Related Experiment Video

Updated: Aug 20, 2026

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

Bertilimumab Cambridge Antibody Technology Group

Changhai Ding1, Jun Li, Xuejue Zhang

  • 1Menzies Research Institute, University of Tasmania, Hobart 7000, Tasmania, Australia. changhai.ding@utas.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|December 3, 2004
PubMed

Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

More Related Videos

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules04:24

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules

Published on: June 16, 2023

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Concept Videos

Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...